Laufende Studien

ROSETTA Breast-01
fortgeschritten/metastasiert
triple negativ, PD-L1 negativ
1^st line

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

INAVO123
fortgeschritten/metastasiert
HR+ / HER2- / PIK3CA+
1^st line

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123)

KANDELA-302
fortgeschritten/metastasiert
HR+ / HER2-
1^st line

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

BREnnA
fortgeschritten/metastasiert
HER2+
mindestens 1 palliative Vortherapie

A two-part, seamless, multicenter, randomized, open-label, adaptive phase II/III study of the blood-brain barrier penetrant RO7771950 versus tucatinib, both in combination with trastuzumab and capecitabine, in patients with pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases

ASCENT-05
post-neoadjuvant
triple negativ

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

GeparPiPPa
neoadjuvant
HER2+/ HR+/ PIK3CA mutiert

A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer

EmpowHER 208
neoadjuvant
HER2+

A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer

TroFuse-032
neoadjuvant
triple negativ oder HR low+ / HER2-
high-risk

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Sigvie-003
Stadium IIIB, IIIC, IV
PD-L1 TC ≥50%
1^st line

An open-label, randomized, controlled phase 3 study of sigvotatug vedotin in combination with pembrolizumab compared with pembrolizumab monotherapy as first-line treatment in participants with PD-L1 high (≥50% of tumor cells expressing PD-L1), locally advanced, unresectable, or metastatic non-small cell lung cancer

PADL1NK-005
Stadium IIIB, IIIC, IV
PD-L1 TPS≥50%
Vorbehandelte Patienten (2L+)

A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

BGB-11417-304
1^st line CLL

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia

CLL 16
Hochrisiko CLL
1^st line

A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk (17P-deletion, TP53-mutation or Complex Karyotype) Chronic Lymphatic Leukemia (CLL)

BGB-16673-302
r/r CLL/SLL
>1 Vortherapie inklusive
cBTKi, BCL2i und ncBTKi

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

DREAMM-15
r/r Multiples Myelom
2^nd / 3^rd line Therapie

A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)